SavedAdd your journal

Journals / Marmara Medical Journal / 2018 / Cilt: 31 - Sayı: 2

CYP 2D6* 4 polymorphism in Polycythemia vera patients in Turkish population

Türk popülasyonunda Polisitemia vera hastalarında CYP 2D6*4 polimorfizmi

Zehra OKAT
Kezban UÇAR ÇİFTÇİ
Kübra YAMA
Selina TOPLAYICI
Elif KURT
Yavuz TAGA
Pages
61–67
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: Many studies have shown the association of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Many studies have shown the association of
📊
Key Findings & Data:Objective: Many studies have shown the association of
💡
Conclusion & Impact:Objective: Many studies have shown the association of
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Sitokrom P450 2D6 · Genetik polimorfizm · Polisitemia vera (PV)

Abstract

Objective: Many studies have shown the association of

Özet

Amaç: Birçok çalışma, ksenobiyotiklerin biyotransformasyonundan

🔖

Cite This Article

OKAT, Z., ÇİFTÇİ, K. U., YAMA, K., TOPLAYICI, S., KURT, E., TAGA, Y. (2018). CYP 2D6* 4 polymorphism in Polycythemia vera patients in Turkish population. Marmara Medical Journal, Cilt: 31 - Sayı: 2, 61–67. https://ajindex.com/articles/284294

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33:313-20. doi: 10.1055/s-2007-976165.
  2. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2003; 200-24. doi: 10.1182/ asheducation-2003.1.200. Tefferi A. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. Seminars in Hematology 1999; 36:3–8.
  3. Bilgrami S, Greenberg, B R. Polycythemia rubra vera. Semin Oncol 1995; 22:307-26. Samuelsson J. Survival in a patient with polycthemia vera for over thirty years: implications for treatment decisions in younger patients. Leukemia and Lymphoma 1998; 32:195-8. doi: 10.3109/10428199809059262. Gonzalez FJ, Tukey RH, (editors). Drug Metabolism: How Humans Cope with Exposure to Xenobiotics.” Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill, 2012. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008; 21:70-83. doi: 10.1021/tx700079z. Bock KW, Lilienblum W, Fischer G, et al. The role of conjugation reactions in detoxication. Arch Toxicol 1987; 60:22-29.
  4. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154:103-16.
  5. Abraham JE, Maranian MJ, Driver KE, et al. CYP 2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64. doi: 10.1186/bcr2629. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13:434-9.
  6. Bertilsson L, Dahl ML, Dalén P and Al-Shurbaji A. Molecular genetics of CYP 2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53:111-22. doi: 10.1046/j.0306-5251.2001.01548.x. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-95.
  7. Hanioka N, Kimura S, Meyer UA, et al. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP 2D6 allele results in an aberrant 3’ splice recogniti